The Europe Reishi Mushroom Market is expected to witness market growth of 7.6% CAGR during the forecast period (2022-2028).
Many aspects of what creates and protects cancer are still unknown, but research on reishi mushrooms indicates that frequent use may help the body fight cancer cells. In addition to being found to stop the growth of cancer, studies suggest that the reishi mushroom could also help the body get rid of any cancer cells that are already present. A study on the effects of ganoderic acid, a triterpinoid contained in the reishi mushroom, on the prevention of tumour growth and metastasis was published in Pharmacological Reports in 2010.
Reishi's impact on the cardiovascular system has been studied. The ganoderic acids were reportedly responsible for lowering high blood pressure. There have been reports of reishi triterpenes that inhibit the angiotensin-converting enzyme. In vitro and animal studies have shown reduced lipid peroxidation, increased antioxidase activity, reduced platelet aggregation, and inhibition of cholesterol production.
When 1.44 g/day of lingzhi or a placebo was given to patients with borderline increased blood pressure and/or cholesterol, a randomized, double-blind, crossover trial found no substantial improvements in blood pressure, body mass index, glycemic indices, lymphocytes, antioxidant capacity, cortisol, urine catecholamines, or cortisone levels. Only apo-B substantially rose in the placebo group, resulting in the only meaningful change in the lipid profile.
There is a sizable mushroom trade in the European Union. Approximately 27% of the annual production of mushrooms is produced in the European Union. The Netherlands, France, and Spain are the region's major producers and consumers. Poland is indeed the top exporter and the leading importer among EU nations, respectively. Additionally, as per NABARD, Germany consumes 17% of all mushroom products, followed by the UK and France, each with 11% of the market. Furthermore, German consumers are more informed than ever before, suggesting that they are making fewer and fewer purchases, but with high standards for quality and a strong desire for health and wellbeing, organic products is expected to present profitable chances for local market players.
The Germany market dominated the Europe Reishi Mushroom Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $327.3 million by 2028. The UK market is estimated to grow at a CAGR of 6.8% during (2022 - 2028). Additionally, The France market is expected to experience a CAGR of 8.4% during (2022 - 2028).
Based on End Use, the market is segmented into Pharmaceutical, Nutraceutical & Dietary Supplements, Food & Beverages and Cosmetics & Personal Care. Based on Form, the market is segmented into Powder and Liquid. Based on Nature, the market is segmented into Conventional and Organic. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Hokkaido Reishi Co. Ltd., Alphay International, Inc., Bio-Botanica, Inc., Bristol Botanicals Limited, Ron Teeguarden Enterprises, Inc., DXN Holdings Bhd., Xi'an Greena Biotech Co., Ltd., Nammex, JHS Natural Products, Inc. (Mushroom Science)
Many aspects of what creates and protects cancer are still unknown, but research on reishi mushrooms indicates that frequent use may help the body fight cancer cells. In addition to being found to stop the growth of cancer, studies suggest that the reishi mushroom could also help the body get rid of any cancer cells that are already present. A study on the effects of ganoderic acid, a triterpinoid contained in the reishi mushroom, on the prevention of tumour growth and metastasis was published in Pharmacological Reports in 2010.
Reishi's impact on the cardiovascular system has been studied. The ganoderic acids were reportedly responsible for lowering high blood pressure. There have been reports of reishi triterpenes that inhibit the angiotensin-converting enzyme. In vitro and animal studies have shown reduced lipid peroxidation, increased antioxidase activity, reduced platelet aggregation, and inhibition of cholesterol production.
When 1.44 g/day of lingzhi or a placebo was given to patients with borderline increased blood pressure and/or cholesterol, a randomized, double-blind, crossover trial found no substantial improvements in blood pressure, body mass index, glycemic indices, lymphocytes, antioxidant capacity, cortisol, urine catecholamines, or cortisone levels. Only apo-B substantially rose in the placebo group, resulting in the only meaningful change in the lipid profile.
There is a sizable mushroom trade in the European Union. Approximately 27% of the annual production of mushrooms is produced in the European Union. The Netherlands, France, and Spain are the region's major producers and consumers. Poland is indeed the top exporter and the leading importer among EU nations, respectively. Additionally, as per NABARD, Germany consumes 17% of all mushroom products, followed by the UK and France, each with 11% of the market. Furthermore, German consumers are more informed than ever before, suggesting that they are making fewer and fewer purchases, but with high standards for quality and a strong desire for health and wellbeing, organic products is expected to present profitable chances for local market players.
The Germany market dominated the Europe Reishi Mushroom Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $327.3 million by 2028. The UK market is estimated to grow at a CAGR of 6.8% during (2022 - 2028). Additionally, The France market is expected to experience a CAGR of 8.4% during (2022 - 2028).
Based on End Use, the market is segmented into Pharmaceutical, Nutraceutical & Dietary Supplements, Food & Beverages and Cosmetics & Personal Care. Based on Form, the market is segmented into Powder and Liquid. Based on Nature, the market is segmented into Conventional and Organic. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Hokkaido Reishi Co. Ltd., Alphay International, Inc., Bio-Botanica, Inc., Bristol Botanicals Limited, Ron Teeguarden Enterprises, Inc., DXN Holdings Bhd., Xi'an Greena Biotech Co., Ltd., Nammex, JHS Natural Products, Inc. (Mushroom Science)
Scope of the Study
Market Segments Covered in the Report:
By End Use- Pharmaceutical, Nutraceutical & Dietary Supplements
- Food & Beverages
- Cosmetics & Personal Care
- Powder
- Liquid
- Conventional
- Organic
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Hokkaido Reishi Co. Ltd.
- Alphay International, Inc.
- Bio-Botanica, Inc.
- Bristol Botanicals Limited
- Ron Teeguarden Enterprises, Inc.
- DXN Holdings Bhd.
- Xi'an Greena Biotech Co., Ltd.
- Nammex
- JHS Natural Products, Inc. (Mushroom Science)
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Europe Reishi Mushroom Market by End Use
Chapter 4. Europe Reishi Mushroom Market by Form
Chapter 5. Europe Reishi Mushroom Market by Nature
Chapter 6. Europe Reishi Mushroom Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Hokkaido Reishi Co. Ltd.
- Alphay International, Inc.
- Bio-Botanica, Inc.
- Bristol Botanicals Limited
- Ron Teeguarden Enterprises, Inc.
- DXN Holdings Bhd.
- Xi'an Greena Biotech Co., Ltd.
- Nammex
- JHS Natural Products, Inc. (Mushroom Science)
Methodology
LOADING...
